JW0201 + C2103

**JW0201 + C2103** is a combination therapy investigated as a potential treatment for Type 2 Diabetes Mellitus. JW0201 is a small molecule drug candidate developed by JW Pharmaceutical, evaluated for its glucose-lowering effects when combined with other agents. C2103 is a separate compound, sometimes also referenced as part of combination clinical studies. The mechanism of action and chemistry of C2103 are not clearly described in the available sources, but the combination has been evaluated for pharmacokinetic interactions, safety, and efficacy in healthy participants and patients with Type 2 Diabetes Mellitus. Clinical studies focus on how these drugs interact and their collective effects on blood glucose regulation when administered orally.